NCT03501251View on ClinicalTrials.gov

Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura

PHASE2CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

August 11, 2018

Study Completion Date

August 11, 2018

Conditions
Trichuris Trichiura; Infection
Interventions
DRUG

Moxidectin 8mg

Participants will receive the tablet with clean water and a package of biscuits.

DRUG

Moxidectin 8 mg + albendazole 400 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 16 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 16 mg + albendazole 400 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 24 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 24 mg + albendazole 400 mg

Participants will receive the tablets with clean water and a package of biscuits.

OTHER

Placebo

Participants will receive the tablet with clean water and a package of biscuits.

Trial Locations (1)

Unknown

Public Health Laboratory Ivo de Carneri, P.O. Box 122, Chake Chake

All Listed Sponsors
collaborator

Public Health Laboratory Ivo de Carneri

OTHER

lead

Swiss Tropical & Public Health Institute

OTHER

NCT03501251 - Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura | Biotech Hunter | Biotech Hunter